Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03248037 · ClinicalTrials.gov registry record · Phase 3
Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation
A Phase 3 study, sponsored by Cornea Research Foundation of America.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT03248037 is a Phase 3 study that has completed, run by Cornea Research Foundation of America. The registered enrollment target is 120 participants.
The verdict
NCT03248037, a Phase 3 study, has completed, sponsored by Cornea Research Foundation of America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.
Interventions
- DRUG Placebo
- DRUG Netarsudil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2019-07-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03248037
The ClinicalTrials.gov registry entry for NCT03248037 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cornea Research Foundation of America, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03248037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03248037 about?
NCT03248037 is a clinical study titled "Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation". Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.
What is the current status of trial NCT03248037?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2017-09-05. Estimated completion is 2019-07-09.
What interventions are being tested in trial NCT03248037?
The interventions under investigation include: Placebo (DRUG), Netarsudil (DRUG).
Who is sponsoring clinical trial NCT03248037?
This trial is sponsored by Cornea Research Foundation of America, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.